ARWR - Goldman starts Arrowhead at neutral cites RNAi portfolio validation
2024-06-05 11:50:05 ET
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals: Hoping Something Sticks
- Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript
- Arrowhead says phase 3 trial of rare metabolic disease asset plozasiran meets goals
- Arrowhead Pharmaceuticals Q2 2024 Earnings Preview